WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

WuXi AppTec (02359) hat aufgrund von Wandelanleihen 98.232 Aktien ausgegeben https://m.jrj.com.cn/madapter/hk/2021/02/08180731871567.shtml Zhitong Finance APP News, WuXi AppTec (02359), gab bekannt, dass 98.232 H-Aktien auf der Grundlage von USD 300 Millionen Nullkupon-Wandelanleihen mit einer Laufzeit bis 2024 zu einem Ausgabepreis von 79,85 HK $ pro Aktie konvertiert und ausgegeben werden.

Von BMS zu Wuxi: Chinesischer Pharmakonzern kommt in die Schweiz https://www.handelszeitung.ch/news/von-bms-zu-wuxi-chinesischer-pharmakonzern-kommt-in-die-schweiz Bristol Myers Squibb verkauft seinen Standort im Kanton Neuenburg an die WuXi STA: Das Unternehmen aus Schanghai übernimmt Anlagen und Personal. ... Die Übernahme in der Schweiz soll es Wuxi STA ermöglichen, die europäischen Märkte besser zu bedienen. Die Anlage in Couvet dient der Produktion von Arzneimitteln insbesondere in Kapsel- und Tabletten-Form.  Wuxi STA ist eine Tochtergesellschaft von Wuxi AppTec in Schanghai – einem Pharma-, Biotech- und Medtech-Konzern mit rund 14'000 Beschäftigten.  

Subsidiary of WuXi AppTec (02359) subscribes for 110 million yuan private equity fund shares https://m.jrj.com.cn/madapter/hk/2021/01/27173631791289.shtml Wuxi AppTec (02359) announced that on January 27, 2021, Wuxi AppTec's Phase I Investment Enterprise (Limited Partnership) (hereinafter referred to as "Wuxi PharmaTech Phase I") Zhuhai Tong, Yucheng Investment Management Partnership (Limited Partnership) and other limited partners signed a partnership agreement, agreeing that WuXi Phase I would subscribe to Zhuhai Tong and Yucheng Investment Partnership (Limited Partnership) for the third phase of RMB 110 million shares , Accounting for 9.982% of the investment fund shares that have been raised.  WuXi Phase I has not paid the investment funds on the date of this announcement, and will use its own funds to fulfill the investment payment obligations in accordance with the requirements of the partnership agreement. According to the announcement, the investment fund has raised RMB 1.102 billion. The investment fund is a limited partnership established in Hengqin New District, Zhuhai City, China, focusing on innovative investment opportunities in the life sciences and healthcare industries.

Gerne

Danke @ Summer. 76 fur die Info 👍👍

Zhongtai International: WuXi AppTec's target price of 217.3 Hong Kong dollars is raised to buy rating https://finance.sina.cn/hkstock/gsxw/2021-01-25/detail-ikftpnny1560254.d.html?from=wap

WuXi AppTec Yingxi and its subsidiary WuXi Biologics reach new highs https://www.881903.com/news/finance/2375846 WuXi AppTec (02359 HK) issued a profit forecast. It is estimated that last year's net profit increased by 50 to 60%, about 927 million to 1.112 billion yuan, mainly due to the rapid growth of overseas customer orders in the second half of the year, the continuous improvement of capacity utilization and operating efficiency. Revenue grew strongly, rising by more than 30% year-on-year in the second half of the year. WuXi AppTec reached a record high of RMB 203.8 and is now up 11%. Its subsidiary WuXi Biologics (02269 HK) also broke the top, rising 8% to RMB 124.

WUXI APPTEC (02359 HK) Sees FY20 NP Up 50%-60% http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1070989/hk-stock-news WUXI APPTEC  has issued a positive profit alert, expecting a 50% to 60% growth in the net profit attributable to shareholders for the year of 2020 as compared with RMB1.855 billion for the year of 2019.

Citi: First to WuXi AppTec (02359) with a target price of HK$236, rating "Buy" https://finance.sina.cn/hkstock/ggyw/2021-01-20/detail-ikftpnnx9695874.d.html?from=wap Citi released a research report that China's pharmaceutical R&D outsourcing and production outsourcing (CRO/CDMO) companies have relatively good cost efficiency and a growing talent pool, and are the first to give the next four companies a "buy" rating.   ... Citi stated that the cost of Chinese pharmaceutical outsourcing companies is 30%-60% lower than that of manufacturers in developed countries. CRO/CDMO companies in China are less affected by public health incidents. According to data from consulting firm Frost & Sullivan, the Chinese R&D outsourcing market The scale in 2019 is US$6.9 billion, and it is expected to reach US$16.9 billion in 2023. The above four companies are the leaders in their fields, and the compound annual growth rate of profit in 2019-2023 is expected to be between 24%-40%.

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1070604/hk-stock-news Citi initiates WUXI APPTEC at Buy with TP $236